Breaking News

Marken Opens Beijing Depot

March 7, 2013

Expands pharmaceutical service network

Marken has opened its new pharmaceutical depot in Beijing, China, providing 850 m2 of GMP compliant space for temperature controlled storage and distribution of clinical trial supplies. The new pharmaceutical depot is co-located with Marken’s Beijing branch office to provide an integrated service to clients.
Marken's depots provide temperature controlled storage and distribution for pharmaceuticals, biologics, medical devices and diagnostic equipment. The company has global depots in Germany, Singapore, the U.S., Argentina, and Mexico, all of which are connected through the Solo platform, a 21 CFR part 11 validated, cloud based inventory management system which tracks dosages at the patient level.
Wes Wheeler, chief executive officer of Marken, said, "We are proud to expand our pharmaceutical service depot network to Beijing, China. We are now pushing forward with more depots in key countries around the world such as Brazil, Chile, Columbia and Russia. Through expanded investment in facilities and technologies, we will continue to ensure that our clients are provided with full service, global clinical supply chain solutions that provide the highest quality courier and logistics services to our clients."

Related Packaging:

blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision